Drugs / HLX23
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04797468 | Jul 2022 → Jan 2023 | neoplasm | Shanghai Henlius Biotech | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-06-01 | Shanghai Henlius Biotech | Regulatory Henlius Received IND Approval for Its Novel Anti-CD73 mAb HLX23 from US FDA henlius.com ↗
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the investigational new drug application for its HLX23 (recombinant anti-CD73 fully humanized monoclonal antibody injection) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced solid tumors. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-06-01 | Shanghai Henlius Biotech | Henlius Received IND Approval for Its Novel Anti-CD73 mAb HLX23 from US FDA henlius.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX23 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04797468 ↗ |
| Action | Inhibit | “CD73 inhibitor HLX23” NCT04797468 ↗ |
| Modality | Monoclonal antibody | “HLX23 (recombinant anti-CD73 humanized monoclonal antibody)” NCT04797468 ↗ |
| Route | Intravenous | “administered IV.” NCT04797468 ↗ |